Skip to main content
SpringerLink
Log in

Antiretroviral therapy 2006: Pharmacology, applications, and special situations

  • Review
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

As we approach the completion of the first 25 years of the human immunodeficiency virus (HIV) epidemic, there have been dramatic improvements in the care of patients with HIV infection. These have prolonged life and decreased morbidity. There are twenty currently available antiretrovirals approved in the United States for the treatment of this infection. The medications, including their pharmacokinetic properties, side effects, and dosing are reviewed. In addition, the current approach to the use of these medicines is discussed. We have included a section addressing common comorbid conditions including hepatitis B and C along with tuberculosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aarnoutse, R. E., Grintjes, K. J., Telgt, D. S., Stek, M., Hugen, P. W., Reiss, P., Koopmans, P. P., Hekster, Y.A., and Burger, D. M., The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.Clin. Pharmacol. Ther., 71, 57–67 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Acosta, E. P., Page, L. M., and Fletcher, C. V., Clinical pharmacokinetics of zidovudine.Clin. Pharmacokinet., 30, 251–262 (1996).

    Article  PubMed  CAS  Google Scholar 

  • Adkins, J. C. and Noble, S., Efavirenz.Drugs, 56, 1055–1064 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Alberti, A., Clumeck, N., Collins, S., Gerlich, W., Lundgren, J., Palu, G., Reiss, P., Thiebaut, R., Weiland, O., Yazdanpanah, Y., and Zeuzem, S., Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.J. Hepatol., 42, 615–624 (2005).

    Article  PubMed  Google Scholar 

  • American College of Obstetricians and gynecologists Committee Opinion. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Number 234. Washington DC: The American College of Obstetricians and Gynecologists, May (2000).

    Google Scholar 

  • Antoniou, T. and Tseng, A. L., Interactions between recreational drugs and antiretroviral agents.Ann. Pharmacother., 36, 1598–1613 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Arvieux, C. and Tribut, O., Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.Drugs, 65, 633–659 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Bartlett, J. A., Zalcitabine, p. 49–59. In Dolin R, Masur H, and Saag MS (ed), AIDS Therapy. Churchill Livingstone, Philadelphia, (1999).

    Google Scholar 

  • Baxter, J. D., Mayers, D. L., Wentworth, D. N., Neaton, J. D., Hoover, M. L., Winters, M. A., Mannheimer, S. B., Thompson, M. A., Abrams, D. I., Brizz, B. J., Ioannidis, J. P., and Merigan, T. C., A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.AIDS., 14, F83–93 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Benhamou, Y., Bochet, M., Thibault, V., Di Martino, V., Caumes, E., Bricaire, F., Opolon, P., Katlama, C., and Poynard, T., Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.Hepatology, 30, 1302–1306 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Benhamou, Y., Bochet, M., Thibault, V., Calvez, V., Fievet, M. H., Vig, P., Gibbs, C. S., Brosgart, C., Fry, J., Namini, H., Katlama, C., and Poynard, T., Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.Lancet., 358, 718–723 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Benhamou, Y., Tubiana, R., and Thibault, V., Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.N. Engl. J. Med., 348, 177–178 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Bergshoeff, A., Burger, D., Verweij, C., Farrelly, L., Flynn J., Le Prevost, M., Walker, S., Novelli, V., Lyall, H., Khoo, S., and Gibb, D., for the PENTA-13 Study Group. Plasma pharmacokinetics of once-versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).Antivir. Ther., 10, 239–246 (2005)

    PubMed  CAS  Google Scholar 

  • Bodsworth, N. J., Cooper, D. A., and Donovan, B., The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state.J. Infect. Dis., 163, 1138–1140 (1991).

    PubMed  CAS  Google Scholar 

  • Bonacini, M., Lin, H. J., and Hollinger, F. B., Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus.J. AIDS., 26, 340–344 (2001).

    CAS  Google Scholar 

  • Bonnet, F., Bonarek, M., Morlat, P., Mercie, P., Dupon, M., Gemain, M. C., Malvy, D., Bernard, N., Pellegrin, J. L., and Beylot, J., Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study.Clin. Infect. Dis., 36, 1324–1328 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Bossi, P., Colin, D., Bricaire, F., and Caumes, E., Hypersensitivity syndrome associated with efavirenz therapy.Clin. Infect. Dis., 30, 227–228 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Bozzette, S. A., Ake, C. F., Tam, H. K., Chang, S. W., and Louis, T. A., Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.N. Engl. J. Med., 348, 702–710 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A., and Koopmans, P. P., Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway.AIDS., 12, 1735–1744 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Bristol-Myers Squibb. Important drug warning: January 5, 2001. Rockville, Md.: Food and Drug Administration, 2001 Accessed February 15 2006, at http://www.fda.gov/medwatch/safety/2001/zerit&videx_letter.htm

    Google Scholar 

  • Brook, M. G., McDonal, J. A., Karayiannis, P., Caruso, L., Forster, G., Harris, J. R., and Thomas, H. C., Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response.Gut., 30, 1116–1122 (1989).

    Article  PubMed  CAS  Google Scholar 

  • Brunelle, M. N., Jacquard, A. C., Pichoud, C., Durantel, D., Carrouee-Durantel, S., Villeneuve, J. P., Trepo, C., and Zoulim, F., Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.Hepatology, 41, 1391–1398 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Buti, M. and Esteban, R., Drugs in Development for Hepatitis B.Drugs., 65, 1451–1460 (2005).

    Article  PubMed  CAS  Google Scholar 

  • CDC. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. Recommendations from the US Department of Health and Human Services.MMWR, 54, RR-2 (2005).

    Google Scholar 

  • CDC. Treating Opportunistic Infections among HIV-infected adults and adolescents. Recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America.MMWR, 53, RR-15 (2004).

    Google Scholar 

  • CDC. Updated US Public health service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis.MMWR, 54, RR-9 (2005).

    Google Scholar 

  • Cameron, D. W., Japour, A. J., Xu, Y., Hsu, A., Mellors, J., Farthing, C., Cohen, C., Poretz, D., Markowitz, M., Follansbee, S., Angel, J. B., McMahon, D., Ho, D., Devanarayan, V., Rode, R., Salgo, M., Kempf, D. J., Granneman, R., Leonard, J. M., and Sun, E., Ritonavir and saquinavir combination therapy for the treatment of HIV infection.AIDS., 13, 213–224 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Campo, R. E., Lalanne, R., Tanner, T. J., Jayaweera, D. T., Rodriguez, A. E., Fotaine, L., and Kolber, M. A., Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients.AIDS., 19, 447–449 (2005).

    Article  PubMed  Google Scholar 

  • Carr, A., Samaras, K., Chisholm, D. J., and Cooper, D. A., Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystropy, hyperlipidemia, and insulin resistance.Lancet., 352, 1881–1883 (1998).

    Article  Google Scholar 

  • Cervia, J. S. and Smith, M. A., Enfuvirtide (T-20): A novel human immunodeficiency virus type 1 fusion inhibitor.Clin. Infect. Dis., 37, 1102–1106 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Chamot, E., Hirschel, B., Wintsch, J., Robert, C. F., Gabriel, V., Deglon, J. J., Yerly, S., and Perrin, L., Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users.AIDS., 4, 1275–1277 (1990).

    Article  PubMed  CAS  Google Scholar 

  • Chapman, T. M., Plosker, G. L., and Perry, C. M., Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection.Drugs., 64, 2101–2124 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Clavel, F. and Hance, A. J., HIV Drug Resistance.N. Engl. J. Med., 350, 1023–1035 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Clevenbergh, P., Corcostegui, M., Gerard, D., Hieronimus, S., Mondain, V., Chichmanian, R. M., Sadoul, J. L., and Dellamonica, P., latrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen.J. Infection., 44, 194–195 (2002).

    Article  CAS  Google Scholar 

  • Cohen, C. J., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, S., Nadler, J., Verbiest, W., Hertogs, K., Ames, M., Rinehart, A. R., Graham, N. M., and the VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.AIDS., 16, 579–588 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Colfax, G. N., Buchbinder, S. P., Corneliss, P. G., Vittinghoff, E., Mayer, K., and Celum, C., Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion.AIDS., 16, 1529–1535 (2002).

    Article  PubMed  Google Scholar 

  • Colin, J. F., Cazals-Hatem, D., Loriot, M. A., Martinot-Peignoux, M., Pham, B. N., Auperin, A., Degott, C., Benhamou, J. P., Erlinger, S., Valla, D., and Marcellin P., Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.Hepatology, 29, 1306–1310 (1999)

    Article  PubMed  CAS  Google Scholar 

  • Collier, A. C., Coombs, R. W., Schoenffeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V.J., Friedman, H. M., Merigan, T. C., Reichman, R. C., Hooper, C., and Corey, L., Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine.N. Engl. J. Med., 334, 1011–1017 (1996).

    Article  PubMed  CAS  Google Scholar 

  • Connor, E. M., Sperling, R. S., Gelber, R., and Kiselev, P., Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment.N. Engl. J. Med., 331, 1173–1180 (1994).

    Article  PubMed  CAS  Google Scholar 

  • Cooper, C. L., van Heeswijk, R. P. G., Gallicano, K., and Cameron, D. W., A Review of Low-Dose Ritonavir in Protease Inhibitor Combination Therapy.Clin. Infect. Dis., 36, 1585–1592 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Cooper, E. R., Charurat, M., Mofenson, L., Hanson, I. C., Pitt, J., Diaz, C., Hayani, K., Handelsman, E., Smeriglio, V., Hoff, R., Blattner, W., and the Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission.J. Acquir. Immune Defic. Syndr., 29, 484–494 (2002).

    PubMed  CAS  Google Scholar 

  • Croom, K. F., and Keam, S. J., Tipranavir, A ritonavir boosted protease inhibitor.Drug, 65, 1669–1677 (2005).

    Article  CAS  Google Scholar 

  • D'Aquila, R. M., Hughes, M. D., Johnson, V. A., Fischl, M. A., Sommadossi, J. P., Liou, S.-H. Timpone, J., Myers, M., Basgoz, N., Niu, M., and Hirsch, M. S., Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection.Ann. Intem. Med., 124, 1019–1030 (1996).

    Google Scholar 

  • Darby, S. C., Ewart, D. W., Giangrande, P. L., Spooner, R. J., Rizza, C. R., Dusheiko, G. M., Lee, C. A., Ludlam, C. A., and Preston, F. E., Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation.Lancet., 350, 1425–1431 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Deeks, S. G., Wrin, T., Liegler, T., Hoh, R., Hayden, M., Barbour, J. D., Hellmann, N. S., Petropoulos, C. J., McCune, J. M., Hellerstein, M. K., and Grant, R. M., Virologic and immunologic consequences of discontinuing combination antiretroviraldrug therapy in HIV-infected patients with detectable viremia.N. Engl. J. Med., 344, 472–480 (2001).

    Article  PubMed  CAS  Google Scholar 

  • de Franchis, R., Hadengue, A., Lau, G., Lavanchy, D., Lok, A., McIntyre, N., Mele, A., Paumgartner, G., Pietrangelo, A., Rodes, J., Rosenberg, W., Valla, D., and the EASL Jury. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version).J. Hepatol., 39 (Suppl 1), S3–25 (2003).

    Google Scholar 

  • Demeter, L. M., and Reichman, R. C., Delavirdine, p 97–105. In Dolin, R., Masur, H., and Saag, MS (ed), AIDS Therapy. Churchill Livingstone, Philadelphia. (1999).

    Google Scholar 

  • den Brinker, M., Wit, F. W., Wertheim-van Dillen, P. M., Jurriaans, S., Weel, J., van Leeuwen, R., Pakker, N. G., Reiss, P., Danner, S. A., Weverling, G. J., and Lange, J. M., Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.AIDS., 14, 2895–2902 (2000).

    Article  Google Scholar 

  • Detels, R., Munoz, A., McFarlane, G., Kingsley, L. A., Margolick, J. B., Giorgi, J., Schrager, L. K., and Phair, J. P., Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration.JAMA., 280, 1497–1503 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Dickover, R. E., Garratty, E. M., Herman, S. A., Sim, M. S., Plaeger, S., Boyer, P. J., Keller, M., Deveikis, A., Stiehm, E. R., and Bryson, Y. J, Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load.JAMA., 275, 599–605 (1996).

    Article  PubMed  CAS  Google Scholar 

  • di Martino, V., Lunel, F., Cadranel, J. F., Hoang, C., Parlier, Y., Le Charpentier, Y., and Opolon, P., Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitisB. J. Vir. Hepat., 3, 253–260 (1996).

    Article  Google Scholar 

  • Di Martino, V., Thevenot, T., Boyer, N., Degos, F., and Marcellin, P., Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients.Hepatology, 31, 1030–1031 (2000).

    PubMed  Google Scholar 

  • Di Martino, V., Rufat, P., Boyer, N., Renard, P., Degos, F., Martinot-Peignoux, M., Matheron, S., Le Moing, V., Vachon, F., Degott, C., Valla, D., and Marcellin, P., The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.Hepatology, 34, 1193–1199, (2001).

    Article  PubMed  Google Scholar 

  • Di Martino, V., Thevenot, T., Colin, J. F., Boyer, N., Martinot, M., Degos, F., Coulaud, J. P., Vilde, J. L., Vachon, F., Degott, C., Valla, D., and Marcellin, P., Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.Gastroenterology, 123, 1812–1822 (2002).

    Article  PubMed  Google Scholar 

  • Dore, G. J., Cooper, D. A., Barrett, C., Goh, L. E, Thakrar, B., and Atkins, M., Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-confected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.J. Infect. Dis., 180, 607–613 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Dorenbaum, A., Cunningham, C. K., Gelber, R. D., Culnane, M., Mofenson, L., Britto, P., Rekacewicz, C., Newell, M. L., Delfraissy, J. F., Cunningham-Schrader, B., Mirochnick, M., Sullivan, J. L., and the International PACTG 316 Team. Two-dose-intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial.JAMA., 288, 189–198 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L., and Lamarre, D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.J. Virol., 70, 3763–3769 (1996).

    PubMed  CAS  Google Scholar 

  • Dragsted, U. B., Gerstoft, J., Pedersen, C., Peters, B., Duran, A., Obel, N., Castagna, A., Cahn, P., Clumeck, N., Bruun, J. N., Benetucci, J., Hill, A., Cassetti, I., Vernazza, P., Youle, M., Fox, Z., Lundgren, J. D., and the MaxCmin1 Trial Group. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.J. Infect. Dis., 188, 635–642 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Dube, M. P., Disorders of glucose metabolism in patients infected with human immunodeficiency virus.Clin. Infect. Dis., 31, 1467–1475 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Dube, M. P., and Sattler, F. R., Metabolic complications of antiretroviral therapies.AIDS Clin. Care., 10, 41–44 (1998).

    PubMed  CAS  Google Scholar 

  • Dube, M. P., Stein, J. H., Aberg, J. A., Fichtenbaum, C. J., Gerber, J. G., Tashima, K. T., Henry, W. K., Currier, J. S., Sprecher, D., and Glesby, M. J., Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.Clin. Infect. Dis., 37, 613–627 (2003).

    Article  PubMed  Google Scholar 

  • Durant, J., Clevenbergh, P., Halfon, P., Delgiudice, P., Porsin, S., Simonet, P., Montagne, N., Boucher, C. A., Schapiro, J. M., and Dellamonica, P., Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.Lancet., 353, 2195–2199 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., and Pau, A. K., Guidelines for Using Antiretroviral Agents Among HIV-Infected Adults and Adolescents.MMWR., 51(RR7), 1–64 (2002).

    PubMed  Google Scholar 

  • El-Sadr, W. and Neaton, J., Episodic CD4-guided use of antiretroviral therapy is inferior to continuous therapy: results of the SMART study. Abstract 106LB Conference on Retroviruses and Opportunistic Infections. Denver, CO. U.S.A., (2006).

  • Eskild, A., Magnus, P., Petersen, G., Sohlberg, C., Jensen, F., Kittelsen, P., and Skaug, K., Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS.AIDS., 6, 571–574 (1992).

    Article  PubMed  CAS  Google Scholar 

  • Esnouf, R. M., Ren, J., Hopkins, A. L., Ross, C. K., Jones, E. Y., Stammers, D. K., and Stuart, D. I., Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.P. Natl. Acad. Sci. U.S.A., 94, 3984–3989 (1997).

    Article  CAS  Google Scholar 

  • The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one.AIDS., 13, 1377–1385 (1999).

    Article  Google Scholar 

  • Fargioin, S., Fracanzani, A. L., and Valenti, L., Treatment Choices for people infected with HCV.J. Antimicrob. Chemother., 53, 708–712 (2004).

    Article  CAS  Google Scholar 

  • Feng, J. Y., Myrick, F. T., Margot, N. A., Mulamba, G. B., Rimsky, L., Borroto-Esoda, K., Selmi, B., and Canard, B., Virologic and enzymatic studies revealing the mechanism of K65R-and Q151m-associated HIV-1 drug resistance towards emtricitabine and lamivudine.Nucleos. Nucleot. Nucl., 25, 89–107 (2006).

    Article  CAS  Google Scholar 

  • Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J, Markowitz, M., Ho, D. D., Richman, D. D., and Siliciano, R. F., Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.Science, 278, 1295–300 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Fischl, M. A., Zidovudine, p. 17–31. In Dolin, R., Masur H., and Saag MS (ed), AIDS Therapy. Churchill Livingstone, Philadelphia. (1999).

    Google Scholar 

  • Fish, D. E., Hay, A., Waters, J. A., McGarvey, M. J., Main, J., and Thomas, H. C., Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection.J. Clin. Pathol., 43, 203–205 (1990).

    Article  PubMed  Google Scholar 

  • Flexner, C., HIV-protease inhibitors.N., Engl. J. Med., 338, 1281–1292 (1998).

    Article  CAS  Google Scholar 

  • Folks, T. M., and Hart, C. E., The life cycle of human immunodeficiency virus type 1, p 29–44. In DeVita Jr VT, Hellman S and Rosenberg, SA (ed), AIDS. Lippincott-Raven Publishers, Philadelphia. (1997).

    Google Scholar 

  • Foster, R. H., and Faulds, D., Abacavir.Drugs, 55, 729–736 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L. Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., and Yu, J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N. Engl. J. Med., 347, 975–982 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Friedland, G. H., Pollard, R., Griffith, B., Hughes, M., Morse, G., Bassett, R., Freimuth, W., Demeter, L., Connick, E., Nevin, T., Hirsch, M., and Fischl, M., Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3.J. AIDS., 21, 281–292 (1999).

    CAS  Google Scholar 

  • Friis-Moller, N., Sabin, C. A., Weber, R., d'Arminio Monforte, A., El-Sadr, W. M., Reiss, P., Thiebaut, R., Morfeldt, L. De Wit, S., Pradier, C., Calvo, G., Law, M. G., Kirk, O., Phillips, A. N., and Lundgren, J. D., Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction.N. Engl. J. Med., 349, 1993–2003 (2003).

    Article  PubMed  Google Scholar 

  • Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., Toole, J. J., and Cheng, A. K., Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.N. Engl. J. Med., 354, 251–260 (2006).

    Article  PubMed  CAS  Google Scholar 

  • Gallant, J. E., and Deresinski, S., Tenofovir disoproxil fumarate.Clin. Infect. Dis., 37, 944–950 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Gallant, J. E., Rodriguez, A. E., Weinberg, W. G., Young, B., Berger, D. S., Lim, M. L., Liao, Q., Ross, L., Johnson, J., and Shaefer, M. S. ESS30009 Study. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.J. Infect. Dis., 192, 1921–1930 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Gallant, J. E., Staszewski, S., Pozniak, A. L., DeJesus, E., Suleiman, J. M., Miller, M. D., Coakley, D. F., Lu, B., Toole, J. J., and Cheng, A. K., 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.JAMA., 292, 191–201 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Gao, H. Q., Boyer, P. L., Sarafianos, S. G., Arnold, E., and Hughes, S. H., The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.J. Molec. Biol., 300, 403–418 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Garcia, P. M., Kalish, L. A., Pitt, J., Minkoff, H., Quinn, T. C., Burchett, S. K., Kornegay, J., Jackson, B., Moye, J., Hanson, C., Zorrilla, C., and Lew, J. F., Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission.N. Engl. J. Med., 341, 394–402 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Garcia-Samaniego, J., Rodriguez, M., Berenguer, J., Rodriguez-Rosado, R., Carbo, J., Asensi, V., and Soriano, V., Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C.Am. J. Gastroenterol., 96, 179–183 (2001).

    PubMed  CAS  Google Scholar 

  • Gathe, J. C. Jr., Ive, P., Wood, R., Schurmann, D., Bellos, N. C., DeJesus, E., Gladysz, A., Garris, C., and Yeo, J., SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.AIDS., 18, 1529–1537 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Gerberding, J. L., Prophylaxis for occupational exposure to HIV.Ann. Intern. Med., 125, 497–501 (1996).

    PubMed  CAS  Google Scholar 

  • Gerard, Y., Maulin, L., Yazdanpanah, Y., De La Tribonniere, X., Amiel, C., Maurage, C. A., Robin, S., Sablonniere, B., Dhennain, C., and Mouton, Y., Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy.AIDS., 14, 2723–2730 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Gerstoft, J., Dragsted, U. B., and Cahn, P., Final analysis of a randomized trial to evaluate safety and efficacy of indinavir/ritonavir versis saquinavir/ritonavir in adult HIV-1 infection: the MAXCmin 1 trial [abstract P29]. 6th International Congress on Drug Therapy in HIV Infection (Glasgow). London: Lippincott Williams & Wilkins, (2002).

    Google Scholar 

  • Gerstoft, J., Mallolas, J., and Lundgren, J., A randomized trial comparing continued indinavir vs. switching to indinavir plus ritonavir in HIV patients having suppressed viral load with indinavir plus two nucleoside analogue reverse transcriptase inhibitors: the best study [abstract O-8]. In: 8th European Conference on Clinical aspects and Treatment of HIV Infection. Athens (2001).

  • Greub, G., Ledergerber, B., Battegay, M., Grob, P., Perrin, L., Furrer, H., Burgisser, P., Erb, P., Boggian, K., Piffaretti, J. C., Hirschel, B., Janin, P., Francioli, P., Flepp, M., and Telenti, A., Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.Lancet., 356, 1800–1805 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Grinspoon, S., and Carr, A., Cardiovascular risk and body-fat abnormalities in HIV infected adults.N. Engl. J. Med., 352, 48–62 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., Emini, E. A., and Chodakewitz, J. A., Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.N. Engl. J. Med., 337, 734–739 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Jonas, L., Meibohm, A., Holder, D., Schleif W. A., Condra, J. H., Emini, E. A., Isaacs, R., Chodakewitz, J. A., and Richman, D. D., Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection.JAMA., 280, 35–41 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Gulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K. E., Meyer, W. A. 3rd., Acosta, E. P., Schackman B. R., Pilcher, C. D., Murphy, R. L., Maher, W. E., Witt, M. D., Reichman, R. C., Snyder, S., Klingman, K. L., and Kuritzkes, D. R., AIDS Clinical Trials Group Study A5095 Team. Triplenucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.N. Engl. J. Med., 350, 1850–1861 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., Chodakewitz, J. A., and Fischl, M. A., A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less.N. Engl. J. Med., 337, 725–733 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Hanna, G. J., and Hirsch, M. S., New Drugs in Development p. 263–272 In Dolin R., Masur, H, and Saag MS (ed), AIDS Therapy. Churchill Livingstone, Philadelphia. (2003).

    Google Scholar 

  • Haubrich, R. H., Kemper, C. A., Hellmann, N. S., Keiser, P. H., Witt, M. D., Tilles, J. G., Forthal, D. N., Leedom, J., Leibowitz, M., McCutchan, J. A., Richman, D. D. and the California Collaborative Treatment Group. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy CCTG 575.AIDS., 19, 295–302 (2005).

    PubMed  Google Scholar 

  • Havlir, D. V., Marschner, I. C., Hirsch, M. S., Collier, A. C., Tebas, P., Bassett, R. L., Ioannidis, J. P. A., Holohan, M. K., Leavitt, R., Boone, G., Richman, D. D., Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy.N. Engl. J. Med., 339, 1261–1268 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Havlir, D. V., and O'Marro, S. D., Atazanavir: New Option for Treatment of HIV Infection.Clin. Infect. Dis., 38, 1599–1604 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Hecht, F. M., Grant, R. M., Petropoulos, C. J., Dillon, B., Chesney, M. A., Tian, H., Hellmann, N. S., Bandrapalli, N. I., Digilio, L., Branson, B., and Kahn, J. O., Brief Report: Sexual Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors.N. Engl. J. Med., 339, 307–311 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Hewitt, R. G., Abacavir hypersensitivity reaction.Clin. Infect. Dis., 34, 1137–1142 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Hilts, A. E., and Fish, D. N., Dosage adjustment of antiretroviral agents in patients with organ dysfunction.Am. J. Health-Syst. Pharm., 55, 2528–2533 (1998).

    PubMed  CAS  Google Scholar 

  • Hinrichsen, H., Benhamou, Y., Wedemeyer, H., Reiser, M., Sentjens, R. E., Calleja, J. L., Forns, X., Erhardt, A., Cronlein, J., Chaves, R. L., Yong, C. L., Nehmiz, G., and Steinmann, G. G., Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.Gastroenterol., 127, 1347–1355 (2004).

    Article  CAS  Google Scholar 

  • Hirsch, M. S., Azidothymidine.J. Inf. Dis., 157, 427–430 (1998).

    Google Scholar 

  • Hirsch, M. S., Brun-Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D'Aquila, R. T., Demeter, L. M., Hammer, S. M., Johnson, V. A., Loveday, C., Mellors, J. W., Jacobsen, D. M., and Richman, D. D., Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.Clin. Infect. Dis., 37, 113–128 (2003).

    Article  PubMed  Google Scholar 

  • Hoff, J., Bani-Sadr, F., Gassin, M., and Raffi, F., Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.Clin. Infect. Dis., 32, 963–969 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Hoffman-LaRoche, Inc. Roferon-A Package Insert. (2001).

  • Hoofnagle, J. H., and Di Bisceglie, A. M., Drug Therapy: The Treatment of Chronic Viral Hepatitis.N. Engl. J. Med., 336, 347–356 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Hughes, M. D., Johnson, V. A., Hirsch, M. S., Bremer, J. W., Elbeik, T., Erice, A., Kuritzkes, D. R., Scott, W. A., Spector, S. A., Basgoz, N., Fischl, M. A., and D'Aquila, R. T., Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response.Ann. Intern. Med., 126, 929–938 (1997).

    PubMed  CAS  Google Scholar 

  • Hurst, M., and Noble, S., Stavudine: an update of its use in the treatment of HIV infection.Drugs, 58, 919–949 (1998).

    Article  Google Scholar 

  • Imhof, A., Ledergerber, B., Gunthard, H. F., Haupts, S., and Weber, R., Swiss HIV Cohort Study. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring?.Clin. Infect. Dis., 41, 721–728 (2005).

    Article  PubMed  Google Scholar 

  • The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. A meta-analysis of 15 prospective cohort studies.N. Engl. J. Med., 340, 977–987 (1999).

    Article  Google Scholar 

  • Ioannidis, J. P. A., Abrams, E. J., Ammann, A., Bulterys, M., Goedert, J. J., Gray, L., Korber, B. T., Mayaux, M. J., Mofenson, L. M., Newell, M. L., Shapiro, D. E., Teglas, J. P., and Wilfert, C. M., Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL.,J. Infect. Dis., 183, 539–545 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Iversen, A. K., Shafer, R. W., Wehrly, K., Winters, M. A., Mullins, J. I., Chesebro, B., and Merigan, T. C., Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.J. Virol., 70, 1086–1090 (1996).

    PubMed  CAS  Google Scholar 

  • Japour, A., Lertora, J., Meehan, P. M., Erice, A., Connor, J. D., Griggith, B. P., Clax, P. A., Holden-Wiltse, J., Hussey, S., Walesky, M., Cooney, E., Pollard, R., Timpone, J., McLaren, C., Johanneson, N., Wood, K., Booth, D., Bassiakos, Y., and Crumpacker, C. S., A phase I study on the safety, pharmacokinetics and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease (ACTG 231 protocol).JAIDS., 13, 235–246 (1996).

    PubMed  CAS  Google Scholar 

  • Jarvis, B., and Faulds, D., Nelfinavir. A. review of its therapeutic efficacy in HIV infection.Drugs., 56, 147–167 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Joint United Nations Programme on HIV/AIDS (UNAIDS), and World Health Organization (WHO). Global Summary of the AIDS Epidemic. AIDS epidemic update: December 2005, 1–2 (2005).

  • Jourdain, G., Ngo-Giang-Huong, N., LeCour, S., Bowonwatanuwong, C., Kantipong, P., Leechanachai, P., Ariyadej, S., Leenasirimakul, P., Hammer, S., Lallemant, M., and the Perinatal HIV Prevention Trial Group. Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy.N. Engl. J. Med., 351, 229–240 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Kakuda, T., and Brinkman, K., Mitochondrial toxic effects of ribavirin.Lancet., 357, 1802–1803 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Katlama, C. Berger, D., Bellos, N., Grinsztejn, B., Haubrich R., Wilkin, T., Monlina, J. M. Steinhart, C., Pedro, R., de Bethune, M. P., De Meyer, S. Hoetelmans, R., Parys, W., Vangeneuden, T., and Lefebvre, E., Efficacy of TMC 114/r in 3 class experienced patients with limited treatment options: 24 week planned interim analysis of 2 96 week multinational dosefinding trials. Abstract 164LB Conference on Retroviruses and Opportunistic Infections, Boston, MA. U.S.A. (2005).

  • Katner, H. P., Paar, D. P., Nadler, J. P., Jensen, E. H., Wilson, H. M., Finn, T. S., Petruschke, R. A., and Zeldin, R. K., Openlabel study of a twice-daily indinavir 800-mg/ritonavir 200 mg regimen in HIV-infected adults failing a protease inhibitor regimen.J. AIDS., 483–487 (2002).

  • Karrer, U., Ledergerber, B., Furrer, H., Elzi, L., Battegay, M., Cavassini, M., Gayet-Ageron, A., Hirschel, B., Schmid, P., Russotti, M., Weber, R., and Speck, R. F., Swiss HIV Cohort Study. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.AIDS., 19, 1987–1994 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Katlama, C., and Havlir, D. V., Newer nucleosides: lamivudine and stavudine.AIDS., 10,(supple A), S135-S143 (1996).

    Article  PubMed  Google Scholar 

  • Kearney, B. P. Mittan, A., Sayre, J., Flaherty, J. F., Zhong, L., Toole, J. J., and Cheng, A. K., Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir. Abstract A-1617. ICAAC September 2003 Chicago III.

  • Kearney, B. P., Flaherty, J. F., and Shah, J., Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.Clin. Pharm., 43, 595–612 (2004).

    Article  CAS  Google Scholar 

  • Kempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., McDonald, E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., Sun, E., Pizzuti, D., Plattner, J. J., Norbeck, D. W., and Leonard, J. M., Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.Antimicrob. Agents. Chemother., 41, 654–660 (1997).

    PubMed  CAS  Google Scholar 

  • Keswani, S. C., Pardo, C. A., Cherry, C. L., Hoke, A., and McArthur, J. C., HIV-associated sensory neuropathies.AIDS., 16, 2105–2117 (2002).

    Article  PubMed  Google Scholar 

  • Kilby, J. M., Inhibitors of HIV attachment and fusion. P. 252–262. In Dolin R., Masur H, and Saag MS (ed), AIDS Therapy. Churchill Livingstone, Philadelphia. (1999).

    Google Scholar 

  • Kilby, J. A. and Eron, J. J., Novel therapies based on mechanisms of HIV-1 cell entry. N.Engl. J. Med., 348, 2228–2238 (2003).

    Article  CAS  Google Scholar 

  • Kilby, J. M., Sfakianos, G., Gizzi, N., Siemon-Hryczyk, P., Ehrensing, E., Oo, C., Buss, N., and Saag, M. S. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.Antimicrob Agents Chemother., 44, 2672–2678 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Kohlbrenner, V. M., Development of a tipranavir mutation score: analysis of protease mutations associated with phenotypic drug susceptibility and antiviral response in Phase II clinical trials. XIII International HIV Drug Resistance Workshop. Tenerife, Spain. (2004).

  • Kosalaraksa, P., Kavlick, M. F., Maroun, V., Le R., and Mitsuya, H., Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in anin vitro competitive HIV-1 replication assay.J. Virol., 73, 5356–5363 (1999).

    PubMed  CAS  Google Scholar 

  • Knudtson, E., Para, M., Boswell, H., and Fan-Havard, P., Drug Rash with Eosinophilia and Systemic Symptoms Syndrome and Renal Toxicity with a Nevirapine-Containing Regimen in a Pregnant Patient with Human Immunodeficiency Virus.Obstet. Gynecol., 101, 1094–1097 (2003).

    Article  PubMed  Google Scholar 

  • Konopnicki, D., Mocroft, A., de Wit, S., Antunes, F., Ledergerber, B., Katlama, C., Zilmer, K., Vella, S., Kirk, O., Lundgren, J. D., and the EuroSIDA Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.AIDS, 19, 593–601 (2005).

    Article  PubMed  Google Scholar 

  • Kuhn, L., Abrams, E. J., Matheson, P. B., Thomas, P. A. Lambert, G., Bamji, M., Greenberg, B., Steketee, R. W., Thea, D. M., for the New York City Perinatal HIV Transmission Collaborative Study Group Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results.AIDS., 11, 429–435 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Kurowski, M., Kaeser, B., Sawyer, A., Popescu, M., and Mrozikiewicz A., Low-dose ritonavir moderately enhances nelfinavir exposure.Clin. Pharmacol. Ther., 72, 123–132 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Lafeuillade, A., Hittinger, G., and Chapadaud, S., Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.Lancet., 357, 280–281 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J. Jr., Chung, J., DeMasi, R., Donatacci, L., Drobnes, C., Delehanty, J., and Salgo, M., TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.N. Engl. J. Med., 348, 2175–2185 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Lallemant, M., Jourdain, G., LeCoeur, S., Mary, J. Y., Ngo-Giang-Huong, N., Koetsawang, S., Kanshana, S., Mclntosh, K., Thaineua, V., and the Perinatal HIV Prevention Trial (Thailand) Investigators. Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother-to-Child Transmission of HIV-1 in Thailand.N. Engl. J. Med., 351, 217–228 (2004).

    Article  PubMed  Google Scholar 

  • Landau, A., Batisse, D., Piketty, C., Jian, R., and Kazatchkin M., Lack of interference between ribavirin and nucleoside analogues in HIV/HCV coinfected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy.AIDS., 14, 1857–1858 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Larder, B. A., and Kemp, S. D., Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).Science, 246, 1155–1158 (1989).

    Article  PubMed  CAS  Google Scholar 

  • Larder, B. A., Kemp, S. D. and Harrigan, P. R., Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.Science, 269, 696–699 (1995).

    Article  PubMed  CAS  Google Scholar 

  • Lauer, G. M. and Walker, B. D., Hepatitis C Virus Infection.N. Engl. J. Med., 345, 41–52 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Lawrence, J., Mayers, D. L., Hullsiek K. H., Collins, G., Abrams, D. I., Reisler, R. B., Crane, L. R., Schmetter, B. S., Dionne, T. J., Saldanha, J. M., Jones, M. C., and Baxter, J. D., 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.N. Engl. J. Med., 349, 837–846 (2003).

    Article  PubMed  Google Scholar 

  • Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arasteh, K., Nelson, M., Katlama, C., Stellbrink, H. J., Delfraissy, J. F., Lange, J., Huson, L., DeMasi, R., Wat, C., Delehanty, J., Drobnes, C., and Salgo, M., TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.N. Engl. J. Med., 348, 2186–2195 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Ledergerber, B., Egger, M., Erard, V., Weber, R., Hirschel, B., Furrer, H., Battegay, M., Vernazza, P., Bernasconi, E., Opravil, M., Kaufmann, D., Sudre, P., Francioli, P., and Telenti, A., AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy.JAMA., 282, 2220–2226 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Lee, W. M., Medical Progress: Hepatitis B Virus Infection.N. Engl. J. Med., 337, 1733–1745 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Le Tiec, C., Barrail, A., Goujard, C., and Taburet, A. M., Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.Clin. Pharmacokinet., 44, 1035–50 (2005).

    Article  PubMed  Google Scholar 

  • Levine, S., Hernandez, D., Yamanaka, G., Zhang, S., Rose, R., Weinheimer, S., and Colonno R. J., Efficacies of Entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerasesin vitro.Antimicrob. Agents. Chemother., 46, 2525–2532 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Lisziewicz, J., Rosenberg, E., Lieberman, J., Jessen, H., Lopalco, L., Siliciano, R., Walker, B., and Lori, F., Control of HIV despite the discontinuation of antiretroviral therapy.N. Engl. J. Med., 340, 1683–1684 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Little, S. J., Holte, S., Routy, J.-P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., Kilby, M., Wang, L., Whitcomb, J. M., Hellmann, N. S., and Richman, D. D., Antiretroviral-Drug Resistance among Patients Recently Infected with HIV.N. Engl. J. Med., 347, 385–394 (2002a).

    Article  PubMed  CAS  Google Scholar 

  • Little, S. J., Daar, E. S., Holte, S., Frost, S., Routy, J. P., Markowitz, M., Collier, A. C., Margolick, J. B., Koup, R. A., Conway, B., Connick, E., Kilby, M., Wrin, T., Petropoulos, C. J., Hellmann, N. S., and Richman, D. D., Persistence of transmitted drug resistance among subjects with primary HIV infection not receiving antiretroviral therapy. In: 9th Conference on Retroviruses and Opportunistic Infections. Abstract 95. (2002b).

  • Lurie, P., Miller, S., Hecht, F., Chesney, M., and Lo, B., Postexposure prophylaxis after nonoccupational HIV exposure.JAMA., 280, 1769–1773 (1998).

    Article  PubMed  CAS  Google Scholar 

  • McDowell, J. A., Chittick G. E., Ravitch, J. R., Polk, R. E., Kerkering, T. M., and Stein, D. S., Pharmacokinetics of abacavir, a human immunodeficiency virus type 1 reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.Antimicrob. Agents. Chemother., 43, 2855–2861 (1999).

    PubMed  CAS  Google Scholar 

  • McMahon, B. J., Epidemiology and natural history of hepatitis B.Sem. Liver. Disease., 1 (25 Suppl), 3–8 (2005).

    Article  Google Scholar 

  • Maitland, D., Moyle, G., Hand, J., Mandalia, S., Boffito, M., Nelson, M., and Gazzard, B., Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.AIDS. 19, 1183–1188 (2005)

    Article  PubMed  CAS  Google Scholar 

  • Malik, A., Abraham, P., and Malik, N., Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature.J. Infect. 51, E61–65 (2005).

    Article  PubMed  Google Scholar 

  • Marcelin, A. G., Delaugerre, C., Wirden, M., Viegas, P., Simon, A., Katlama, C., and Calvez, V., Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.J. Med. Virol., 72, 162–165 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Marcellin, P., Asselah, T., and Boyer, N., Treatment of chronic hepatitis B.J. Viral. Hepatit., 12, 333–345 (2005).

    Article  CAS  Google Scholar 

  • Marrone, A., Zampino, R., Karayannis, P., Cirillo, G., Cesaro, G., Guerrera, B., Ricciotti, R., del Giudice, E. M., Utili, R., Adinolfi, L. E., and Ruggiero, G., Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.Aliment. Pharm. Therap., 22, 707–714 (2005).

    Article  CAS  Google Scholar 

  • Martin, A., Smith, D. E., Carr, A., Ringland, C., Amin, J., Emery, S., Hoy, J., Workman, C., Doong, N., Freund, J., and Cooper, D. A., Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.AIDS., 18, 1029–1036 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Martinez, E., Armaiz, J. A., Podzamczer, D., Dalmau, D., Ribera, E., Domingo, P., Knobel, H., Riera, M., Pedrol, E., Force, L., Llibre, J. M., Segura, F., Richart, C., Cortes, C., Javaloyas, M., Aranda, M., Cruceta, A., de Lazzari, E., and Gatell, J. M., Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.N. Engl. J. Med., 349, 1036–1046 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., Phair, J. P., and Rinaldo, C. R., Plasma viral load and CD4+ Lymphocytes as prognostic markers of HIV-1 infection.Ann. Intern. Med., 126: 946–954 (1997).

    PubMed  CAS  Google Scholar 

  • Mellors, J. W., Rinaldo, C. R., Gupta, P., White, R. M., Todd, J. A. and Kingsley, L. A., Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.Science, 272, 1167–1170 (1996)

    Article  PubMed  CAS  Google Scholar 

  • Menzo, S., Castagna, A., Monachetti, A., Hasson, H., Danise, A., Carini, E., Bagnarelli, P., Lazzarin, A., and Clementi, M., Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.Antimicrob. Agents. Chemother., 48, 3253–3259 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Meynard, J. L., Vray, M., Morand-Joubert, L., Race, E., Descamps, D., Peytavin, G., Matheron, S., Lamotte, C., Guiramand, S., Costagliola, D., Brun-Vezinet, F., Clavel, F., Girard, P. M., and the Narval Trial Group. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.AIDS., 16, 727–736 (2002).

    Article  PubMed  Google Scholar 

  • Miller, V., Mocroft, A., Reiss, P., Katlama, C., Papadopoulos, A. I., Katzenstein, A., Van Lunzen, J., Antunes, F., Phillips, A. N., and Lundgren, J. D., Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.Ann. Interm. Med., 130, 570–577 (1999).

    CAS  Google Scholar 

  • Miller, V., Staszewski, S., Boucher, C. A. and Phair, J. P., Clinical experience with non-nucleoside reverse transcriptase inhibitors.AIDS., 11, (suppl A), S157-S164 (1997).

    PubMed  Google Scholar 

  • Minkoff, H. and Augenbraun, M., Antiretroviral therapy for pregnant women.Am. J. Obstet. Gynecol., 176, 478–489 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Mock, P. A., Shaffer, N., Bhadrakom, C., Siriwasin, W., Chotpitayasunondh T., Chearskul, S., Young, N. L., Roongpisuthipong, A., Chinayon, P., Kalish, M. L., Parekh, B., and Mastro, T. D., Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand.AIDS., 13, 407–414 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Mocroft, A., Youle, M., Phillips, A. N., Halai, R., Easterbrook, P., Johnson, M. A. and Gazzard, B., The incidence of AIDS-defining illnesses in 4883 patients with human immunode-ficiency virus infection.Arch. Intern. Med., 158, 491–497 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Mofenson, L. M., Lambert, J. S., Stiehm, E.R., Bethel, J., Meyer, W. A., Whitehouse, J., Moye, J., Reichelderfer, P., Harris, D. R., Fowler, M. G., Mathieson, B. J., and Nemo, G. J., Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine.N. Engl. J. Med., 341, 385–393 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Mofenson, L. M. and the U.S. Public Health Service Task Force Recommendations for Use—of Antiretroviral Drugs in Pregnant HIV-1—Infected Women for Maternal Health and Interventions To Reduce Perinatal HIV-1 Transmission in the United States.MMWR., 51 (RR18), 1–38 (2002).

    PubMed  Google Scholar 

  • Molto, J., Ruiz, L., Romeu, J., Martinez-Picado, J., Negredo, E., Tural, C., Sirera, G., and Clotet, B., Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.AIDS Res. & Hum. Retrovir., 20, 1283–1288 (2004).

    Article  CAS  Google Scholar 

  • Monga, H. K., Rodriguez-Barradas, M. C., Breaux, K., Khattak, K., Troisi, C. L., Velez, M., and Yoffe, B., Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection.Clin. Infect. Dis., 33, 240–247 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Montaner, J. S. G., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., Wainberg, M. A., Smith, D., Robinson, P., Hall, D., Myers, M., and Lange, J. M. A., A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients.JAMA, 279, 930–937 (1998).

    Article  PubMed  CAS  Google Scholar 

  • MMWR. Incidence of Acute Hepatitis B—United States, 1990–2002.MMWR., 51, 1252–1254 (2004).

    Google Scholar 

  • Morsica, G., De Bona, A., Uberti, C., Sitia, G., Finazzi, R., and Lazzarin, A., Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment.AIDS, 14, 1656–1658 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Moyle, G., Pozniak, A., Opravil, M., Clumeck, N., DelFraissy, J.-F., Johnson, M., Pelgrom, J., Reynes, J., Vittecoq, D., DeLora, P., Salgo, M., and Duff, F., The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues.J. AIDS., 23, 128–137 (2000).

    CAS  Google Scholar 

  • Murphy, R. L., Brun, S., and King, M., Lopinavir/ritonavir (Kaletra) in antiretroviral naïve HIV+patients: 4 year follow-up [abstract H-165]. 42nd Interscience on Conference on Antimicrobial Agents and Chemotherapy (San Diego). (2002).

  • Murphy, R. L., Gulick, R. M., DeGruttola, V., D'Aquila, R. T., Eron, J. J., Sommadossi, J.-P., Currier, J. S., Smeaton, L., Frank, I., Caliendo, A. M., Gerber, J. G., Tung, R., and Kuritzkes, D. R., Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection.J. Infect. Dis., 179, 808–816 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., and Miller, A. H., Paroxetine for the Prevention of Depression Induced by High-Dose Interferon Alfa.N. Engl. J. Med., 344, 961–966 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Nduati, R., Grace, J., Mbori-Ngacha, D., Richardson, B., Overbaugh, J., Mwatha, A., Ndinya-Achola, J., Bwayo, J., Onyango, F. E., Hughes, J., and Kreiss, J., Effect of breast-feeding and formula feeding on transmission of HIV-1: a randomised clinical trial.JAMA., 283 1167–1174 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Nottermans, D. W., Pakker, N. G., Hamann, D., Foudraine, N. A., Kauffmann, R. H., Meenhorst, P. L., Goudsmit, J., Roos, M. T. L., Schellekens, P. T. A., Miedema, F., and Danner, S. A., Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults.J. Infect. Dis., 180, 1050–1056 (1999).

    Article  Google Scholar 

  • Núñez, M., Puoti, M., Camino, N., and Soriano, V., Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.Clin. Infect. Dis., 37, 1678–1685 (2003).

    Article  PubMed  Google Scholar 

  • Núñez, M., Maida, I., Berdún, M., and Soriano, V., Efficacy and safety of pegylated interferon a–2a plus ribavirin for the treatment of hepatitis C in HIV-coinfected patients: the PRESCO trial. In: 44th ICAAC, Abstract V-1148 (2004).

  • O'Brien, W. A., Hartigan, P. M., Daar, E. S., Simberkoff, M. S., and Hamilton, J. D., Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to anti-retroviral therapy and therapeutic failure.Ann. Intern. Med., 126, 939–945, (1997).

    PubMed  Google Scholar 

  • Pachl, C., Todd, J. A., and Kern, D. G., Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay.J. AIDS., 8, 446–454 (1995).

    CAS  Google Scholar 

  • Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., and Holmberg, S. D., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.N. Engl. J. Med., 338, 853–60 (1998).

    Article  PubMed  Google Scholar 

  • Department of Health and Human Services. Panel on clinical practices for the treatment of HIV infection-Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. (2005).

  • Panlilio, A. L., Cardo, D. M., Grohskopf, L. A., Heneine, W., and Ross, C. S., Updated U. S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis.MMWR., 54 (RR09), 1–17 (2005).

    PubMed  Google Scholar 

  • Perrillo, R. P., Regenstein, F. G., and Roodman, S. T., Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus.Ann. Intern. Med., 105, 382–3 (1986).

    PubMed  CAS  Google Scholar 

  • Perry, C. M. and Faulds, D., Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.Drugs, 53, 657–680 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Perry, C. M. and Noble, S., Didanosine: An updated review of its use in HIV infection.Drugs, 58, 1099–1135 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Pesce, A., Taillan, B., and Rosenthal, E., Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients.Lancet., 341, 1597 (1993).

    Article  PubMed  CAS  Google Scholar 

  • Pialoux, G., Raffi, F., Brun-Vezinet, F., Meiffredy, V., Flandre, P., Gastaut, J. A., Dellamonica, P., Yeni, P., Delfraissy, J. F., and Aboulker, J. P., A randomized trial of three maintenance regiments given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients.N. Engl. J. Med., 339, 1269–1276 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Picard, V., Angelini, E., Maillard, A., Race, E., Clavel, F., Chene, G., Ferchal, F., and Molina, J. M., Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.J. Infect. Dis., 184, 781–784 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Piroth, L., Duong, M., Quantin, C., Abrahamowicz, M., Michardiere, R., Aho, L. S., Grappin, M., Buisson, M., Waldner, A., Portier, H., and Chavanet, P., Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients?AIDS. 12, 381–388 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Piscitelli, S. C. and Gallicano, K. D., Interactions among drugs for HIV and opportunistic infections.N. Engl. J. Med., 344, 984–996 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Piwoz, E. G., Ross, J., and Humphrey, J., Human immunodeficiency virus transmission during breastfeeding: knowledge, gaps, and challenges for the future.Adv. Exp. Med. Biol., 554, 195–210 (2004).

    PubMed  Google Scholar 

  • Pollard, R. B., Robinson, P., and Dransfield, K., Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection.Clin. Therap., 20, 1071–1092 (1998).

    Article  CAS  Google Scholar 

  • Pomerantz, R. J., How HIV Resists Eradication.Hosp. Pract., 87–101 (1998).

  • Pramoolsinsup, C., Management of viral hepatitis B.J. Gastroen. Hepatol., 17, S125-S145 (2002).

    Article  Google Scholar 

  • Preston, D. B., Poiesz, B. J., and Loeb, L. A., Fidelity of HIV-1 reverse transcriptase.Science, 242 1168–1171 (1998).

    Article  Google Scholar 

  • Public Health Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for matemal health and for reducing perinatal HIV-1 transmission in the United States.MMWR., 47(RR-2) 1–30 (1998).

    Google Scholar 

  • Public Health Service Task Force. Recommendations for Use of Antiretroviral drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States.MMWR., 47, (RR-2) 1–55 (2005).

    Google Scholar 

  • Quaranta, J. F., Delaney, S. R., Alleman, S., Cassuto, J. P., Dellamonica, P., and Allain, J. P., Prevalence of antibody to hepatitis C virus (HCV) in, HIV-1-infected patients (nice SEROCO cohort).J. Med. Virol., 42, 29–32 (1994).

    Article  PubMed  CAS  Google Scholar 

  • Quinn, T. C., Wawer, M. J., Sewankambo, N., Serwadda, D., Li, C., Wabwire-Mangen, F., Meehan, M. O., Lutalo, T., and Gray, R. H., Viral load and heterosexual transmission of immunodeficiency virus type 1.N. Engl. J. Med., 342, 921–929 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Rana, K. Z. and Dudley, M. N., Clinical pharmacokinetics of stavudine.Clin. Pharmacokinet., 33, 276–284 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Resch, W., Parkin, N., Stuelke, E. L., Watkins, T., and Swanstrom, R., A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics.P. Natl. Acad. Sci. U.S.A., 98, 176–181 (2001).

    Article  CAS  Google Scholar 

  • Rodriguez-French, A., Boghossian, J., Gray, G. E., Nadler, J. P., Quinones, A. R., Sepulveda, G. E., Millard, J. M., and Wannamaker, P. G., The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.J. AIDS., 35, 22–32 (2004).

    CAS  Google Scholar 

  • Ristig, M. B., Crippin, J., Aberg, J. A., Powderly, W. G., Lisker-Melman, M., Kessels, L., and Tebas, P., Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.J. Infect. Dis., 186, 1844–1847 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Roberts, J. D., Bebenek, K., and Kunkel, T. A., The accuracy of reverse transcriptase from HIV-1.Science, 242, 1171–1173 (1998).

    Article  Google Scholar 

  • Rockstroh, J. K., Mocroft, A., Soriano, V., Tural, C., Losso, M. H., Horban, A., Kirk, O., Phillips, A., Ledergerber, B., Lundgren, J., and the EuroSIDA Study Group. Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy.J. Infect. Dis., 192, 992–1002 (2005).

    Article  PubMed  Google Scholar 

  • Rodriguez, M., Berenguer, J., Rodriguez-Rosado, R., Carbo, J., Asensi, V. and Soriano, V., Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C.Am. J. Gastroenterol., 96, 179–183 (2001).

    PubMed  Google Scholar 

  • Saag, M. S., Emtricitabine, a new antiretroviral agent with activity against HIV and Hepatitis B Virus.Clin. Infect. Dis., 42, 126–131 (2006).

    Article  PubMed  CAS  Google Scholar 

  • Saag, M. S., Holodniy, M., Kuritzkes, D. R., O'Brien, W. A., Coobs, R., Poscher, M. E., Jacobsen, D. M., Shaw, G. M., Richman, D. D., and Volberding, P. A., HIV viral load markers in clinical practice.Nature. Med., 6, 625–629 (1996).

    Google Scholar 

  • Sabin, C., Staszewski, S., Phillips, A. Rabenau, H., Cozzi Lepri, A., Weidman, E., and Miller, V., Discordant immunological and virological responses to HAART. Abstract 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, U.S.A. (2000).

  • Saksela, K., Stevens, C. E., Rubinstein, P., Taylor, P. E., and Baltimore, D., HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS.Ann. Intern. Med., 123, 641–648 (1995).

    PubMed  CAS  Google Scholar 

  • Salmon-Céron, D., Chauvelot-Moachon, L., Abad, S., Silbermann, B., and Sogni, P., Mitochondrial toxic effects and ribavirin.Lancet, 357, 1803–1804 (2001).

    Article  PubMed  Google Scholar 

  • Samuel, R. and Suh, B., Antiretroviral therapy 2000.Arch. Pharm. Res., 23, 425–437 (2000).

    PubMed  CAS  Google Scholar 

  • Sarisky, R. T., Non-nucleoside inhibitors of the HCV polymerase.J. Anitmicrob. Chemother., 54, 14–16 (2004).

    Article  CAS  Google Scholar 

  • Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S. A., Mulder, J., Loveday, C., and Christopherson, C., Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).J. Infect Dis., 171, 1411–1419 (1995).

    PubMed  CAS  Google Scholar 

  • Scully, C. and Porter, S., HIV topic update: oro-genital transmission of HIV.Oral Dis., 6, 92–98 (2000).

    PubMed  CAS  Google Scholar 

  • Shire, N. J. and Sherman, K. E., Management of HBV/HIV coinfected patients.Seminars in Liver Disease, 25 (Suppl 1), 48–57 (2005).

    Article  PubMed  Google Scholar 

  • Solomon, R. E., VanRaden, M., Kaslow, R. A., Lyter, D., Visscher, B., Farzadegan, H., and Phair, J., Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection.Am. J. Public Health., 80, 1475–1478 (1990).

    PubMed  CAS  Google Scholar 

  • Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, A., Cacoub, P., Katlama, C., Cargnel, A., Mauss, S., Dieterich, D., Moreno, S., Ferrari, C., Poynard, T., and Rockstroh, J., Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.AIDS, 16, 813–828 (2002).

    Article  PubMed  Google Scholar 

  • Soriano, V., Puoti, M., Sulkowski, M., Mauss, S., Cacoub, P., Cargnel, A., Dieterich, D., Hatzakis, A., and Rockstroh, J., Care of patients with hepatitis C and HIV co-infection. Updated recommendations from the HIV-HCV International Panel.AIDS., 18, 1–12 (2004).

    Article  PubMed  Google Scholar 

  • Soriano, V., Martin-Carbonero, L., Maida, I., Garcia-Samaniego, J., and Núñez, M., New paradigms in the management of HIV and hepatitis C virus coinfection.Curr. Opin. Infect. Dis., 18, 550–560 (2005).

    Article  PubMed  Google Scholar 

  • Soto, B., Sanchez-Quijano, A., Rodrigo, L., del Olmo, J. A., Garcia-Bengoechea, M., Hernandez-Quero, J., Rey, C., Abad, M. A., Rodriguez, M., Sales Gilabert, M., Gonzalez, F., Miron, P., Caruz, A., Relimpio, F., Torronteras, R., Leal, M., and Lissen, E., Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis.J. Hepatol., 26, 1–5 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Spengler, U., Lichterfeld, M., and Rockstroh, J. K., Antiretroviral drug toxicity — a challenge for the hepatologist?J. Hepatol. 36, 283–294 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Squires, K., Lazzarin, A., Gatell, J. M., Powderly, W. G., Pokrovskiy, V., Delfraissy, J. F., Jemsek, J., Rivero, A., Rozenbaum, W., Schrader, S., Sension, M., Vibhagool, A., Thiry, A., and Giordano, M., Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.J. AIDS., 36, 1011–1019 (2004).

    CAS  Google Scholar 

  • Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., Manion, D. J., and Ruiz, N. M., Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults.N. Engl. J. Med., 341, 1865–1873 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Steel, H. M., Special presentation on aplaviroc-related hepatotoxicity. Program and abstracts of the European AIDS Clinical Society 10th European AIDS Conference; November 17–20, Dublin, Ireland (2005).

  • Sterling, T. R., Chaisson, R. E., and Moore, R. D., Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity.Clin. Infect. Dis., 36, 812–815 (2003).

    Article  PubMed  Google Scholar 

  • Sulkowski, M. S., Moore, R. D., Mehta, S. H., Chaisson, R. E., and Thomas, D. L., Hepatitis C and progression of HIV disease.JAMA., 288, 199–206 (2002).

    Article  PubMed  Google Scholar 

  • Tedaldi, E. M., Baker, R. K., Moorman, A. C., Alzola, C. F., Furhrer, J., McCabe, R. E., Wood, K. C., and Holmberg, S. D., HIV Outpatient Study (HOPS) Investigators. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.Clin. Infect. Dis., 36, 363–367 (2003).

    Article  PubMed  Google Scholar 

  • Tenney, D. J., Levine, S. M., Rose, R. E., Walsh, A. W., Weinheimer, S. P., Discoto, L., Plym, M., Pokornowski, K., Yu, C. F., Angus, P., Ayres, A., Bartholomeusz, A., Sievert, W., Thompson, G., Warner, N., Locarnini, S., and Colonno, R., J. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine.Antimicrob. Agents. Chemother., 48, 3498–5307 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Thea, D. M., Steketee, R. W., Pliner, V., Bornschlegel, K., Brown, T., Orloff, S., Matheson, P. B., Abrams, E. J., Bamji, M., Lambert, G., Schoenbaum, E. A., Thomas, P. A., Heagarty, M., and Kalish, M. L., The effect of maternal viral load on the risk of perinatal transmission of HIV-1.AIDS., 11, 437–44 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Thio, C. L., Seaberg, E. C., Skolasky, R., Phair, J., Visscher, B., Munoz, A., and Thomas, D. L., for the Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).Lancet., 360, 1921–1926 (2002).

    Article  PubMed  Google Scholar 

  • Thorne, C. and Newell M. L., Treatment options for the prevention of mother-to-child transmission of HIV.Cur. Opin. Invest. Drugs., 6, 804–811 (2005).

    CAS  Google Scholar 

  • Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-Garcia, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., Sette, H. Jr., Passe, S., De Pamphilis, J., Duff, F., Schrenk, U. M., and Dieterich, D. T., for the APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.N. Engl. J. Med., 351, 438–450 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Troisi, C. L., Hollinger, F. B., Hoots, W. K., Contant, C., Gill, J., Ragni, M., Parmley, R., Sexauer, C., Gomperts, E., and Buchanan, G., A multicenter study of viral hepatitis in a United States hemophilic population.Blood, 81, 412–418 (1993).

    PubMed  CAS  Google Scholar 

  • Tuomala, R. E., Shapiro, D. E., Mofenson, L. M., Bryson, Y., Culnane, M., Hughes, M. D., O'Sullivan, M. J., Scott, G., Stek, A. M., Wara, D., and Bulterys, M., Antiretroviral Therapy During Pregnancy and the Risk of an Adverse Outcome.N. Engl. J. Med., 346, 1863–1870 (2002).

    Article  PubMed  Google Scholar 

  • Tural, C., Ruiz, L., Holtzer, C., Schapiro, J., Viciana, P., Gonzalez, J., Domingo, P., Boucher, C., Rey-Joly, C., and Clotet, B., for the Havana Study Group. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.AIDS., 16, 209–218 (2002).

    Article  PubMed  Google Scholar 

  • UNAIDS/WHO. Report on the Global HIV/AIDS Epidemic. January (2006).

  • US Department of Health and Human Services, HIV/AIDS Treatment and Information Service. Safety and toxicity of individual antiretroviral agents in pregnancy, May 17, 2002. In: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.MMWR., 51(RR7), 1–64 (2002).

    Google Scholar 

  • Van Ameijden, E. J., van den Hoek, J. A., Mientjes, G. H., and Coutinho, R. A., A longitudinal study on the incidence and transmission patters on HIV, HBV and HCV infection among drug users in Amsterdam.Eur. J. Epidemiol., 9, 255–262 (1993).

    Article  PubMed  Google Scholar 

  • Van Gemen, B., Van Beuningen, R., and Nabbe, A., A one tube quantitative HIV-1 RNA NASBS nucleic acid amplification assay using electrochemiluminescent (ECL) labeled probes.J. Virolog. Method., 49, 157–168 (1994).

    Article  Google Scholar 

  • van Leth, F., Phanuphak, P., Ruxrungtham, K., Baraldi, E., Miller, S., Gazzard, B., Cahn, P., Lalloo, U. G., van der Westhuizen, I. P., Malan, D. R., Johnson, M. A., Santos, B. R., Mulcahy, F., Wood, R., Levi, G. C., Reboredo, G., Squires, K., Cassetti, I., Petit, D., Raffi, F., Katlama, C., Murphy, R. L., Horban, A., Dam, J. P., Hassink, E., van Leeuwen, R., Robinson, P., Wit, F. W., and Lange, J. M., 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.Lancet., 363, 1253–1263 (2004).

    Article  PubMed  CAS  Google Scholar 

  • van Heeswijk, R. P., Veldkamp, A. I., Hoetelmans, R. M., Mulder, J. W., Schreij, G., Hsu, A., Lange, J. M., Beijnen, J. H., and Meenhorst, P. L., The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.AIDS., 13, F95–99 (1999).

    Article  PubMed  Google Scholar 

  • Veldkamp, A. I., van Heeswijk, R. P., Mulder, J. W., Meenhorst, P. L., Schreij, G., van der Geest, S., Lange, J. M., Beijnen, J. H., and Hoetelmans, R. M., Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.J. AIDS., 27, 344–349 (2001).

    CAS  Google Scholar 

  • Vento, S., Di Perri, G., Cruciani, M., Garofano, T., Concia, E., and Bassetti, D., Rapid decline of CD4+ cells after interferon treatment in HIV-1 infection.Lancet., 341, 958–959 (1993).

    Article  PubMed  CAS  Google Scholar 

  • Vlahov, D., Graham, N., Hoover, D., Flynn, C., Bartlett, J. G., Margolick, J. B., Lyles, C. M., Nelson, K. E., Smith, D., Holmberg, S., and Farzadegan, H., Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users- plasma viral load and CD4+ cell count.JAMA., 279, 35–40 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., Johnson, D., Lalonde, R., Japour, A., Brun, S., and Sun, E., M98-863 Study Team. Lopinavirritonavir versus nelfinavir for the initial treatment of HIV infection.N. Engl. J. Med., 346, 2039–2046 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Watts, D. H., Management of Human Immunodeficiency Virus Infection in Pregnancy.N. Engl. J. Med., 346, 1879–1891 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Weinheimer, S., Discotto, L., Friborg, J., Yang, H., and Colonno, R., Atazanavir signature 150L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.Antimicrob. Agent. Chemother., 49, 3816–3824 (2005).

    Article  CAS  Google Scholar 

  • White, K. L., Margot, N. A., Ly, J. K., Chen, J. M., Ray, A. S., Pavelko, M., Wang, R., McDermott, M., Swaminathan, S., and Miller, M. D., A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT.AIDS., 19, 1751–1760 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Winnock, M., Salmon-Céron, D., Dabis, F., and Chêne, G., Interaction between HIV-1 and HCV infections: towards a new entity?.J. Antimicrob. Chemother., 53, 936–946 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Wolbach, J. and Capoccia, K., A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.Nurse Practitioner., 24, 81–92 (1999).

    PubMed  CAS  Google Scholar 

  • Yerly, S., Perneger, T. V., Hirschel, B., Dubuis, O., Matter, L., Malinverni, R., Furrer, H., and Perrin, L., A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients.Arch. Intern. Med., 158, 247–252 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Ying, C., De Clercq, E., Nicholson, W., Furman, P., and Neyts, J., Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.J. Viral. Hepat., 7, 161–165 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Young, B., Fischl, M. A., Wilson, H. M., Finn, T. S., Jensen, E. H., DiNubile, M. J., and Zeldin, R. K., Open-label study of a twice-daily indinavir 800-mg/ritonavir 100 mg regimen in protease inhibitor-naive HIV-infected adults.JAIDS., 31, 478–482 (2002).

    PubMed  CAS  Google Scholar 

  • Youle, M., Mocroft, A., and Johnson, M., Lipid profiles in patients on ritonavir/indinavir containing salvage regimens [abstract 24].Antivir. Ther., 4, (Suppl 2), 22 (1999).

    Google Scholar 

  • Zhang, Y. M., Imamichi, H., Imamichi, T., Lane, H. C., Falloon, J., Vasudevachari, M. B., and Salzman, N. P., Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.J. Virol., 71, 6662–6670 (1997).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Infectious Diseases, Temple University Hospital, 3401 N Broad St, 19140, Philadelphia, PA, U.S.A.

    Rafik Samuel, Robert Bettiker & Byungse Suh

Authors
  1. Rafik Samuel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Bettiker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Byungse Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rafik Samuel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Samuel, R., Bettiker, R. & Suh, B. Antiretroviral therapy 2006: Pharmacology, applications, and special situations. Arch Pharm Res 29, 431–458 (2006). https://doi.org/10.1007/BF02969415

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02969415

Key words

Search

Navigation